Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention

American Journal of Health-System Pharmacy

Volumn 59, Issue SUPPL. 7, 2002, Pages

  Cheng, Judy W M ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

Abciximab; Angioplasty; Costs; Eptifibatide; Platelet aggregation inhibitors; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0036828670     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/59.suppl_7.s5     Document Type: Conference Paper

References (44)

1. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2001.
2. Kabbani SS, Aggarwal A, Terrien EF et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol. 2002; 89:647-50.
3. Landau C, Lange RA, Hillis LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994; 330:981-93.
4. Gibson CM, Cannon CP, Murphy SA et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000; 101:125-30.
5. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332:1553-9.
6. White HD. Unmet therapeutic needs in the management of acute ischemia. Am J Cardiol. 1997; 80(4A):2B-10B.
7. Wagner CL, Neblock DS, Weisman HF et al. Analysis of GP IIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood. 1996; 88:907-14.
8. Popma JJ, Ohman EM, Weitz J et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001; 119:321S-36S.
9. Bittl JA, Chaitman BR, Feit F et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001; 142:952-9.
10. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet. 2001; 358:527-33.
11. Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Dekker; 1997:291-313.
12. Kleiman NS, Raizner AE, Jordan R et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol. 1995; 26:1665-71.
13. 3 integrins. Circulation. 1998; 98:1085-91.
14. Simon DI, Xu H, Ortlepp S et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997; 17:528-35.
15. Tcheng JE, Kereiakes DJ, Lincoff AM et al. Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation. 2001; 104:870-5.
16. Scarborough RM. Development of eptifibatide. Am Heart J. 1999; 138:1093-104.
17. Harrington RA, Kleiman NS, Kottke-Marchant K et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995; 76:1222-7.
18. Lorenz TJ, Macdonald F, Kitt MM. Non-immunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa. Clin Ther. 1999; 21:128-37.
19. Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Dekker; 1997:355-65.
20. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998; 338:1498-505.
21. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998; 338:1488-97.
22. Coller BS, Folts JD, Smith SR et al. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989; 80:1766-74.
23. Tcheng JE, Ellis SG, George BS et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994; 90:1757-64.
24. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994; 330:956-61.
25. Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet. 1994; 343:881-6.
26. Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta(3) blockade with percutaneous coronary intervention. JAMA. 1997; 278:479-84.
27. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization. N Engl J Med. 1997; 336:1689-96.
28. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998; 352:87-92.
29. Lincoff AM, Califf RM, Moliterno DJ et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 1999; 341:319-27.
30. Topol EJ, Mark DB, Lincoff AM et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet. 1999; 354:2019-24.
31. Bhatt DL, Marso SP, Lincoff AM et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol. 2000; 35:922-8.
32. IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. Lancet. 1997; 349:1422-8.
33. + on GP IIb-IIIa interactions with Integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997; 96:1488-94.
34. Tcheng JE, Talley JD, O'Shea JC et al. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol. 2001; 88:1097-102.
35. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998; 339:436-43.
36. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet. 2000; 356:2037-44.
37. O'Shea JC, Hafley GE, Greenberg S et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA. 2001; 285:2468-73.
38. O'Shea JC, Buller CE, Cantor WJ et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002; 287:618-21.
39. Laskey WK, Williams DO, Vlachos HA et al. Changes in the practice of percutaneous coronary intervention: A comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) dynamic registry. Am J Cardiol. 2001; 87:964-9.
40. Rebeiz AG, Pieper KS, O'Shea JC et al. Sixteen- to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. Circulation. 2001; 104(suppl):II-386. Abstract.
41. Kereiakes DJ, Kleiman NS, Ambrose J et al. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996; 27:536-42.
42. RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997; 96:1445-53.
43. Topol EJ, Moliterno DJ, Herrmann HC et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001; 344:1888-94.
44. Kereiakes DJ, Broderick TM, Roth EM et al. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol. 1999; 84:391-5.